A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 459 participants.

Also called NCT01717300

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 459 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01717300
  • EudraCT 2012-003110-14
Other papers using this trial's data
  • Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol The American journal of cardiology, 2017-02-01 DOI, PubMed 27956003

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01717300. Randomized; double masking; primary purpose treatment. Start 2012-11-06 (actual); primary completion 2014-10-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)
Condition
Hypercholesterolemia
Intervention (Drug)
Anacetrapib 100 mg
Intervention (Drug)
Placebo for anacetrapib 100 mg
Intervention (Drug)
Anacetrapib 25 mg
Intervention (Drug)
Placebo for anacetrapib 25 mg
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01717300
Content hash
732cf22d23e1d0992af65dbd5748486641ea9b43ce94a4eb2ebca2c73709036b